Tag: osé
OSE Immuno: the title soars, partnership with AbbVie – 02/28/2024 at 11:45
(CercleFinance.com) – OSE Immunotherapeutics shares soared on the Paris Stock Exchange on Wednesday following the signing of a strategic partnership with the American biopharmaceutical group AbbVie. Around 11:30 a.m., the…
Ose Immunotherapeutics jumps after its partnership with Abbvie
(AOF) – Ose Immunotherapeutics (+54.61% to 5.11 euros) posts the strongest increase in the SRD market after announcing a global collaboration and licensing agreement with the American Abbvie to develop…
OSE Immunotherapeutics: new positive results against advanced solid tumors
(AOF) – OSE Immunotherapeutics presents the latest positive results from the Phase 1/2 clinical evaluation of its product OSE-279 in advanced solid tumors at the 2024 ESMO Targeted Anticancer Therapies…
OSE Immuno: positive interim analysis of a study – 11/12/2023 at 2:25 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announces that it has presented a positive interim analysis of data from the phase 1/2 clinical trial relating to the first use in kidney transplantation of…
OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30
At the annual congress of the Société Francophone de Transplantation Supported by the European Society of Organ Transplantation (ESOT) Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics…
OSE Immunotherapeutics announces a collaboration agreement with GenDx for the development of a companion diagnostic test associated with Tedopi®, its epitope-based cancer vaccine candidate – 11/21/2023 at 6:00 p.m.
• A development program to support the next pivotal confirmatory phase 3 clinical trial currently being prepared.• A companion diagnostic test to identify HLA-A*02 positive cancer patients eligible for treatment…
OSE Immunotherapeutics enters into collaboration agreement with GenDx
By Alexandra Saintpierre Published on 11/21/2023 at 6:12 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces a collaboration agreement…
Ose immuno: Collaboration agreement with GenDx
Read also (CercleFinance.com) – OSE Immunotherapeutics announces a collaboration agreement with GenDx (Eurobio Scientific Group) to develop and validate a companion diagnostic test (CDx) as part of the preparation of…
OSE Immuno: collaboration agreement with GenDx – 11/21/2023 at 6:09 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announces a collaboration agreement with GenDx (Eurobio Scientific Group) to develop and validate a companion diagnostic test (CDx) as part of the preparation of the pivotal…
OSE Immunotherapeutics joins forces with GenDx for the clinical trial of its anti-cancer vascin – 11/21/2023 at 6:13 p.m.
(AOF) – OSE Immunotherapeutics announced a collaboration agreement with GenDx (Eurobio Scientific Group, a key player in the field of in vitro diagnostics). This will involve developing and validating a…
OSE Immuno: first positive results for an antibody – 10/24/2023 at 10:58
(CercleFinance.com) – OSE Immunotherapeutics was among the biggest risers on the Paris Stock Exchange this Tuesday after the biotechnology company announced the first positive clinical results on its new monoclonal…
OSE Immunotherapeutics: positive results against solid tumors
(AOF) – OSE Immunotherapeutics announces the presentation of the first phase 1 clinical results of BI 770371, a new anti-SIRPα monoclonal antibody evaluated in solid tumors, at the ESMO (European…